<DOC>
	<DOCNO>NCT01615796</DOCNO>
	<brief_summary>GSK2140944 belong Bacterial Type II Topoisomerase Inhibitor ( BTI ) class antibiotic . GSK2140944 demonstrate vitro vivo activity Gram positive pathogen include methicillin resistant Staphylococcus aureus ( MRSA ) Gram-negative pathogen associate respiratory tract , skin soft tissue infection include isolates resistant exist class antimicrobial .</brief_summary>
	<brief_title>Evaluate Safety , Tolerability , Pharmacokinetics Single Repeat IV Doses</brief_title>
	<detailed_description>GSK2140944 belong Bacterial Type II Topoisomerase Inhibitor ( BTI ) class antibiotic . GSK2140944 demonstrate vitro vivo activity Gram positive pathogen include methicillin resistant Staphylococcus aureus ( MRSA ) Gram-negative pathogen associate respiratory tract , skin soft issue infection include isolates resistant exist class antimicrobial . This study first administration GSK2140944 intravenous ( IV ) formulation human conduct two ( 2 ) part . Single IV dos explore Part A repeat IV dose explored Part B . In addition , study evaluate absolute bioavailability oral capsule formulation compare IV formulation Part A . Both study part investigate safety , tolerability pharmacokinetic profile GSK2140944 healthy adult subject .</detailed_description>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin le 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 60 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . To confirm postmenopausal status , blood sample simultaneous follicle stimulate hormone ( FSH ) great 40 MlU/ml estradiol le 40 pg/ml ( le 147 pmol/L ) confirmatory . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication final followup visit . Body weight great equal 50 kg BMI within range 19 31 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen positive Human Immunodeficiency Virus ( HIV ) antibody . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Any clinically significant central nervous system ( e.g. , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition history condition , opinion investigator may place subject unacceptable risk participant trial may interfere absorption , distribution , metabolism excretion drug . A positive urine test drug abuse alcohol ( alcohol breath test ) screening . A screening urinalysis positive protein glucose ( great `` trace '' finding protein glucose ) . A serum creatinine value screen Day 1 visit increase 0.2 mg/dL ( 15.25 umol/L ) change . History photosensitivity quinolones . Unwillingness commit avoid excessive exposure sunlight ( exposure whilst tan bed ) would cause sunburn reaction first dose include followup visit . History drug abuse within 6 month study . History smoking use nicotine containing product within 3 month screen , positive urine cotinine indicative smoking screening . History regular alcohol consumption within 6 month study define average weekly intake great 21 unit ( average daily intake great 3 unit ) male average weekly intake great 14 unit ( average daily intake great 2 unit ) female . One unit equivalent 270 mL full strength beer , 470 mL light beer , 30 mL spirit 100 mL wine . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication , use St. John 's Wort within 14 day prior first dose study medication . By exception , volunteer may take paracetamol acetaminophen ( less equal 2 grams/day ) 48 hour prior first dose study medication . However , Investigator GSK study team review medication case case basis determine use would compromise subject safety interfere study procedure data interpretation . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Donation blood excess 500 mL within 12 week prior dose . Unwillingness inability follow procedure outline protocol . History tendon rupture . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia ( clinical research unit use heparin maintain intravenous cannula patency ) . Consumption red wine , seville orange , grapefruit grapefruit juice , pummelo , exotic citrus fruit , grapefruit hybrid fruit juice contain product 7 day prior first dose study medication . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Heart rate : Males le 40 great 100 bpm ; Females : le 50 great 100 bpm ; PR Interval : Males Females le 120 great 220 msec ; QRS duration : Males Females le 70 great 100 msec ; QTcB QTcF interval : Males Females great 450 msec ; Evidence previous myocardial infarction ( include ST segment change associate repolarization ) ; Subject Bundle Branch Block ; Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) , sinus pause great 3 second , nonsustained sustain ventricular tachycardia ( great equal 3 consecutive ventricular ectopic beat ) significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . Screening holter monitoring show one following : Any symptomatic arrhythmia ( except isolate extra systole ) ; Sustained cardiac arrhythmia ( atrial fibrillation flutter , SVT ( great 10 consecutive beat ) ) ; Sinus tachycardia ( supraventricular tachycardia ) great 150 bpm ; Nonsustained sustain ventricular tachycardia ( define great equal 3 consecutive ventricular ectopic beat ) ; Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high awake subject ] , WPW syndrome , preexcitation syndrome ) ; Symptomatic sinus pause sinus pause &gt; 3 second unless patient straining , vomit , type hypervagal response ; 300 supraventricular ectopic beat 24 hour ; 250 ventricular ectopic beat 24 hour ; Ischemia , diagnose sequence EKG change include flat downsloping STsegment depression great 0.1 mV , gradual onset offset last minimum period 1 minute . Each episode ischemia must separate minimum duration least 1 minute , ST segment return back baseline ( 1x1x1 rule ) . Neutrophil count &lt; 2000 cell per microliter ( single repeat allow eligibility determination ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK2140944</keyword>
	<keyword>antibiotic</keyword>
	<keyword>first time human</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>intravenous</keyword>
	<keyword>safety</keyword>
	<keyword>absolute bioavailability</keyword>
	<keyword>Bacterial Type II</keyword>
	<keyword>tolerability</keyword>
	<keyword>infection</keyword>
</DOC>